1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Global Gene Therapy Consumption Report with Detailed Analysis of Market Applications – Medgadget (blog)

Continue reading

2017-03-14 NEWS

Global Gene Therapy Consumption Report with Detailed Analysis of Market Applications
Medgadget (blog)
Qyresearchreports include new market research report “Gene Therapy” to its huge collection of research reports. This research report on the global Gene Therapy market provides in-depth and information on the key factors that influence the movements in …

and more »
Continue reading

2017-03-14 NEWS

Runner’s World

Stem Cell Therapy
Runner’s World
Stem cells are immature cells that have the ability to grow into many different types of cells. In sports medicine, stem cells are harvested and then injected into an injured area, says Jonathan Finnoff, D.O., professor of physical medicine and …
Has stem cell therapy helped the Boden’s poster girl say her first words? Cerebral palsy patient Holly, 11, shows …Daily Mail
At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific …Benzinga
Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in …PR Newswire (press release)
EurekAlert (press release) –Yahoo Finance –Medgadget (blog)
all 14 news articles »
Continue reading

2017-03-14 NEWS

FierceBiotech

Allergan, Editas partner on CRISPR tech in eye diseases
FierceBiotech
Allergan and gene editing biotech Editas have penned an upfront $90 million CRISPR research pact that will focus on ocular disorders. Under the deal, Allergan gets exclusive access and the option to license up to five of Editas’ genome-editing eye …
Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseasesEndpoints News
Editas and Allergan Partner on Multiple CRISPR Eye Disease ProgramsGenetic Engineering & Biotechnology News
Editas, Allergan Ink $90M CRISPR-Based Eye Drug DealGenomeWeb
BioPharma Dive –StreetInsider.com –EconoTimes
all 30 news articles »
Continue reading

2017-03-14 NEWS

The FINANCIAL

Allergan and Editas Medicine Enter into Strategic R&D Alliance
The FINANCIAL
The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine’s lead program is being …
Continue reading

2017-03-14 NEWS

Endpoints News

Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases
Endpoints News
The biotech struck a deal to partner with CRISPR/Cas9 leader Editas $EDIT on up to five programs aimed at curing eye diseases. And the package includes Editas’ lead program for Leber Congenital Amaurosis (LCA10), which is currently wrapping preclinical …
Allergan (AGN), Editas Medicine (EDIT) Enter Alliance to Discover and Develop CRISPR Genome Editing Medicines …StreetInsider.com
Allergan, Editas partner on CRISPR tech in eye diseasesFierceBiotech
First Trial in Sight, Editas Cuts $90M Eye Drug Deal With AllerganXconomy
Reuters –CNA Finance (press release)
all 14 news articles »
Continue reading

2017-03-14 NEWS
Recent Posts
Blog Categories
Blog Categories
Blog Categories
Blog Categories
Blog Categories

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing …
EconoTimes
The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine’s lead program is being …